Table 2.
Common Treatments for SpA
| Medication | AS | ReA | PsA | IBD-related |
|---|---|---|---|---|
| NSAIDs | + | + | + | + |
| Sulfasalazine | + (a) | + (a) | + (a) | + (a) |
| Methotrexate | + (a) | + (a) | + (a) | + (a) |
| Leflunomide | − | − | + (a) | − |
| Cyclosporine | − | − | + (a) | − |
| Azathioprine | − | − | + (a) | + (a) |
| Mesalamine | − | − | − | + (a) (b) |
| Adalimumab | + | − | + | + |
| Etanercept | + | + (b) | + | + |
| Infliximab | + | − | + | + |
| Golimumab | + | − | + | − |
| Certolizumab | + (b) | − | − | − |
| Abatacept | − | − | + (e) | − |
| Corticosteroids | + (c) | + (c) | + (d) | + |
a = limited effect on axial disease but possible benefit for peripheral disease
b = anecdotal; efficacy seen in case studies
c = intraarticular
d = intraarticular; oral may worsen/cause pustular psoriasis; never inject through psoriatic skin lesion
e = 2011 study showed efficacy